RxDoctor Payments Data

John Ng, MD

Radiation Oncology · New York, NYNPI 1225287048

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,600 of the $4,481 with a category attached, or 80.3%. Hologic Inc accounts for 94.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $4,242 and has fallen 98.9% since, to $45 in 2025.

$4,481in general payments, 2019–2025

Across 8 payments — averaging $560.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hologic Inc$4K
  • Sirtex Medical Inc$134
  • Johnson & Johnson$104
$15,539in research payments, 2019–2025

Across 2 payments — averaging $7769.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viewray Technologies Inc$16K

What the payments were for

  • Consulting fees$3,60080%
  • Travel & lodging$42910%
  • Food & beverage$45210%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Hologic Inc3$4,242
Sirtex Medical Inc1$134
Johnson & Johnson4$104

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,481 in reported general payments places this provider in the 85th percentile of 397 radiation oncology providers in New York.

See all radiation oncology providers in New York

Medicare billing

Part B allowed, 2024
$393,197
Medicare patients
460
Services billed
2,861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →